Thea Pharma launches Iyuzeh in US
Click Here to Manage Email Alerts
Key takeaways:
- Thea Pharma launched Iyuzeh in the United States.
- Iyuzeh is a preservative-free formulation of latanoprost.
Thea Pharma has launched Iyuzeh in the U.S. for the treatment of primary open-angle glaucoma or ocular hypertension.
“Iyuzeh brings similar efficacy of traditional latanoprost, formulated without preservatives, to help eye care providers confidently address their treatment goals of lowering intraocular pressure for people with POAG and OHT,” Susan Benton, president of Thea Pharma, said in a press release.
Image: Adobe Stock
In randomized controlled clinical trials, Iyuzeh (latanoprost ophthalmic solution 0.005%) lowered IOP in patients with primary open-angle glaucoma or ocular hypertension with a mean baseline IOP of 19 mm Hg to 24 mm Hg by 3 mm Hg to 8 mm Hg compared with the reference product Xalatan (latanoprost 0.005%, Viatris), which lowered IOP by 4 mm Hg to 8 mm Hg.
The FDA approved Iyuzeh in December 2022.
Read more about
Click Here to Manage Email Alerts